Stay updated with breaking news from Interim Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NKGen Biotech, Inc. announced an online publication, titled ?Interim Analysis of a Phase I Study using Cryopreserved Non-genetically Modified Allogeneic Natural Killer Cells With Enhanced Cytotoxicity...
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript February 28, 2024 Mirum Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.66 EPS, expectations were $-0.33. MIRM isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and […]
PolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call Transcript February 14, 2024 PolyPid Ltd. misses on earnings expectations. Reported EPS is $-3.97 EPS, expectations were $-2.17. PolyPid Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greeting morning and welcome to […]
More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 New Preclinical Data Showed OncoPLEX Injected Intratumorally Reduced Tumor Volume and Improved Survival in New Animal Models Recent Successful $16 Million Financing Extends Company’s Cash Runway
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2024 -- Denali Therapeutics Inc. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier ...